Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds
Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2θ±0.2°) of 9.7° and/or 21.9° in a powder X-ray diffraction are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation. Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate and amorphous 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate are also suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation.
1. A process for preparing a compound (I), a salt or a hydrate of the foregoing
wherein R 1 represents C1-6 alkyl and R 2 and R 3 independently represent hydrogen or C1-6 alkyl, by allowing a compound (II)
wherein R 1 is as defined above, to react with a compound (III)
wherein R 2 and R 3 are as defined above.
2. A process according to claim 1 , wherein R 1 is methyl.
3. A process according to any one of claims 1 or 2 , wherein R 2 and R 3 are hydrogen.